Clinical trials: Osteoporosis, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Osteoporosis
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Cystic Fibrosis
Markers of Osteoporosis in Cystic Fibrosis
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection.
- Trial name
- NCT03921060
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Osteoporotic Fractures
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
This project anchors osteoporotic fractures, conduct registration and follow-up studies, and conduct prospective treatment studies.
- Trial name
- NCT05866029
- Testing
- Denosumab, Teriparatide
- Where
- 58 sites in China
- Volunteers
- 2,478 people
- Sponsor
- Peking Union Medical College Hospital
Menopausal Osteoporosis, Bone Markers
COMPASS - COpenhagen MenoPAuSe Study
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications.
- Trial name
- COMPASS (NCT07254429)
- Testing
- Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2)
- Where
- Denmark
- Volunteers
- 192 people
- Sponsor
- Martin Blomberg Jensen
Postmenopausal Women With Osteoporosis at High Risk of Fracture
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
- Trial name
- NCT07062978
- Testing
- QL1206, Prolia®
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Circadian Rhythm Disorders, Osteoporosis
Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis
This is a randomized, controlled, and exploratory study designed to evaluate the chronotherapeutic effects of teriparatide administration in postmenopausal osteoporosis.
- Trial name
- NCT06951776
- Testing
- Morning administration group of teriparatide, Evening administration group of teriparatide
- Volunteers
- 28 people
- Sponsor
- Peking University Third Hospital
Type 2 Diabetes, Osteoporosis
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
This study will conduct a randomized controlled trial targeting patients with type 2 diabetes and a high risk of fractures. The aim is to evaluate the intervention effect of denosumab combined with edilossobulin on patients with…
- Conditions
- Type 2 Diabetes, Osteoporosis, Fractures
- Trial name
- NCT07063797
- Testing
- Denosumab treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients, Denosumab combined with eldecalcitol treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients
- Where
- 4 sites in China
- Volunteers
- 358 people
- Sponsor
- Peking Union Medical College Hospital
Chronic Kidney Disease, Osteoporosis
Pharmacokinetics of Zoledronic Acid in Patients on Dialysis
Osteoporosis is a frequent complication of chronic kidney disease (CKD) on dialysis, with an estimated prevalence of approximately 40%. It is associated with increased fracture risk, reduced quality of life, and higher mortality.
- Conditions
- Chronic Kidney Disease, Osteoporosis, Dialysis
- Trial name
- ZADIAL (NCT07741136)
- Testing
- Zoledronic Acid Injection, 5.0 mg, single dose, Zoledronic Acid Injection, 2.5 mg, single dose
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Osteoporosis
Preserving Geriatric Muscle With an Osteoporosis Medication
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
- Trial name
- NCT06118905
- Testing
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Chrissy Kistler
Critical Illness, Osteoporosis
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in…
- Trial name
- BoneZone (NCT04608630)
- Testing
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 450 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Osteoporosis, Osteoporosis, Steroid Induced
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment.
- Conditions
- Osteoporosis, Osteoporosis, Steroid Induced, Inflammatory Rheumatism
- Trial name
- BOOGIE (NCT06395883)
- Testing
- Glucocorticoid Effect
- Where
- 2 sites in Norway
- Volunteers
- 160 people
- Sponsor
- Diakonhjemmet Hospital
Hip Fractures, Osteoporosis
A Study to Improve the Collaboration Between Primary and Secondary Health Care on the Treatment of Osteoporosis After a Hip Fracture.
This is a study to improve the collaboration between primary and secondary health care on the treatment of osteoporosis after a hip fracture.
- Conditions
- Hip Fractures, Osteoporosis, Zoledronic Acid, Ambulant Nurse
- Trial name
- NCT05904353
- Testing
- Ambulant nurse-assisted administration of zoledronic acid, Usual care
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- University Hospital, Akershus
Osteoporosis in Post-menopausal Women
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
The aim of this clinical trial is to investigate the effectiveness of romosozumab started without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures and who is…
- Trial name
- MORD (NCT06720350)
- Testing
- Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Marmara University
Postmenopausal Women With Osteoporosis
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.
- Trial name
- NCT07579936
- Testing
- SAL056 56.5μg, Intervention Group 1, Intervention Group 2
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Postmenopausal Osteoporosis, Low Bone Mass
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone…
- Trial name
- NCT07806331
- Testing
- Denosumab
- Volunteers
- 110 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Osteoporosis, Osteoporotic Vertebral Compression Fractures
Safety and Efficacy Clinical Trial of the Vessel-X® Bone Filling Container System
Osteoporotic vertebral compression fractures (OVCFs) are a common and serious complication of osteoporosis, particularly among elderly and postmenopausal patients.
- Trial name
- CMT-VX (NCT07665424)
- Testing
- CMT Vessel-X® Bone Filling Container System, CMT Manual Orthopedic Surgical Instruments
- Where
- 2 sites in Taiwan
- Volunteers
- 146 people
- Sponsor
- Juin-Hong Cherng
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Postmenopausal Osteoporosis
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures.
- Trial name
- SAFEST (NCT06767150)
- Testing
- a second infusion of ZOL when crosslaps levels reach 300 pg/mL, a rescue second infusion at month-12 (standard traitment)
- Where
- 17 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Toulouse
Sarcopenia in Elderly
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
- Trial name
- NCT06643780
- Testing
- Denosumab, Zolendronic Acid
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Osteoporosis, Postmenopausal
Sequential Therapies After Osteoanabolic Treatment
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics
- Trial name
- START (NCT06164795)
- Testing
- Zoledronate, Denosumab, Teriparatide
- Where
- 8 sites in Greece, Italy
- Volunteers
- 150 people
- Sponsor
- 424 General Military Hospital
Osteoporosis
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects
Primary objective of this study is to evaluate the similarity in pharmacokinetic characteristics between SAL023 Injection and Italy-manufactured Evenity.
- Trial name
- NCT07384104
- Testing
- SAL0123, Romosozumab
- Where
- China
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.